Marshall University

Marshall Digital Scholar
Management Faculty Research

Management, Marketing and MIS

4-1-2012

Can Kawasaki Disease Be Managed?
Alberto Coustasse
Marshall University, coustassehen@marshall.edu

Julius Larry
Doohee Lee
Marshall University, leed@marshall.edu

Follow this and additional works at: http://mds.marshall.edu/mgmt_faculty
Part of the Cardiovascular Diseases Commons, and the Health Services Research Commons
Recommended Citation
Coustasse, A., Larry, J. & Lee, D. (2012). Can Kawasaki Disease be managed? The Permanente Journal, 16(2), 70-72.

This Article is brought to you for free and open access by the Management, Marketing and MIS at Marshall Digital Scholar. It has been accepted for
inclusion in Management Faculty Research by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu.

COMMENTARY

Can Kawasaki Disease Be Managed?
Alberto Coustasse, DrPH, MD, MBA, MPH; Julius Larry, DDS, JD, MPH; Doohee Lee, PhD

Abstract
Kawasaki Disease (KD) is the leading cause of acquired cardiovascular disease
among children, but management of KD has received relatively little attention. In the
US alone, about 5500 cases were estimated in 2009. KD is most common among
Asian and Pacific Islander children but can affect all ethnicities and races. Timely
and accurate diagnosis remains critical, but difficult: the etiology of KD is unknown,
and no accurate diagnostic laboratory test has been developed. Continuing medical
education can help physicians, clinicians, and nurse practitioners accurately diagnose
and treat KD. A registry specific to KD or a surveillance system may be necessary to
increase awareness among health care professionals and to decrease complications
related to misdiagnosis.

What is Kawasaki Disease?
Kawasaki Disease (KD) is an acute
febrile illness that can potentially affect the heart and its larger arteries. It
often affects children younger than five
years.1 KD is also called mucocutaneous lymph node syndrome, because it
involves lymph nodes, skin, and mucous
membranes inside the mouth, nose, and
throat.1,2 According to the American Heart
Association3 and the Centers for Disease
Control and Prevention,1 KD diagnostic
criteria include high fever lasting four or
five days, along with four or more of the
following seven symptoms: 1) rash, 2) red
eyes, 3) red, swollen, and cracked lips,
4) “strawberry” tongue, 5) swollen hands
and feet, 6) swollen lymph nodes, and 7)
redness of the palms and soles of the feet.

Statistics and Recent Trends
In the US alone, about 5500 cases of
KD were estimated in 2009.1 In Japan,
a 2008 nationwide study conducted by
Nakamura et al4 found that 19,138 patients
were suffering from KD during the 2-year
period 2003–2004, revealing the continuation of an upward trend that started in
Japan in the mid-1990s. A survey in 2009
suggested that the incidence is also rising
in India.5 This may be explained by greater
awareness or by rapid industrialization.6
The latest incidence statistics available

for the US are from a 2010 retrospective
national study by Holman et al7: the rate of
hospitalization related to KD in 2006 was
20.8 per 100,000 children younger than
age 5 years. It is more frequent in children
older than 1 year and toddlers ages 1 to 4
years. KD affects all ethnicities and races,
but it is most common among children of
Asian and Pacific Islander descent, with
30.3 cases per 100,000 hospitalizations.
The incidence for non-Hispanic Blacks,
non-Hispanic Whites, and Hispanics is
17.5, 12, and 15.7 cases per 100,000 hospitalizations, respectively.7
KD is the leading cause of acquired
cardiovascular disease in children in the
US.8 The etiology of KD remains unknown
after 40 years of intense research,9 and no
laboratory test can accurately diagnose
KD and atypical cases that are approximate KD but do not meet all diagnostic
criteria for KD.1 Delayed diagnosis and
treatment remain prevalent and unavoidable.10 Diagnosis is further complicated in
that KD shares symptoms and signs with
other illnesses.2 Therefore, the real number of undertreated and misdiagnosed
cases is unknown.11

Diagnosis and Etiology
Virtually all deaths in patients who
have experienced KD result from cardiac
sequelae, or secondary cardiac conditions
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such as arrhythmia, chest pain, myocardial
infarction (MI), and sudden death.12,13
Mortality peaks 15 to 45 days after the
initial onset of fever. However, sudden
death from MI may occur many years
later in individuals who had coronary
artery aneurysms (CAA) and stenoses as
children. The potential for death years
later because of KD complications suggests that it is important to follow KD
patients throughout childhood. Many
cases of fatal and nonfatal MIs in young
adults have been attributed to “missed”
KD in childhood.12
A recent study by Coustasse and associates10 revealed that fewer than half of the
patients in their Texas sample (n = 303)
were correctly diagnosed with KD upon
hospital admission. The majority of KD
cases were misdiagnosed. In their crosssectional analysis, there were 41 admitting diagnoses other than KD. Although
misdiagnosis appears to be common, the
overwhelming majority (> 96%) of children
with KD are hospitalized.14,15 The remaining 4% are treated on an outpatient basis.
Untreated, KD can lead to serious complications that involve the heart and cardiovascular system.2 Because CAA occurs
more frequently in untreated patients,16
effective interventions are required to
enhance clinicians’ ability to accurately
identify KD in children younger than age
5 years presenting with high fever and
rash.17 Treatment within 10 days after
onset of fever is essential to decrease the
risk of heart problems. With appropriate
detection and treatment, the prevalence
of CAA is reduced to as few as 1% and
no more than 5% of cases.18
The Lloyd et al study19 investigated
clinical and epidemiologic features of
KD and emphasized the likelihood of an
infectious cause. Consequently, several
microbial agents have been studied in
connection with KD: Rickettsiae, Propioni-
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bacterium acnes, Klebsiella pneumoniae,
Ehrlichia, parainfluenza virus types 2
and 3, Epstein-Barr virus, and rotavirus,
among others. 20,21 Additional possible
causes for the disease are prior respiratory disease; exposure to carpet cleaning
chemicals; use of humidifiers; and living
in close proximity to lakes, rivers, bays,
or oceans.8,22 Although multiple infectious
agents and toxins have been implicated,
none have been conclusively identified as
a causative or contributing agent.15

Treatment
First-line treatment consists of intravenous immunoglobulin for 8 hours to 12
hours within 10 days of the first onset
of fever. High doses of aspirin must be
administered until the fever subsides.
Aspirin should be continued and gradually tapered for at least 2 months to reduce the risk of spontaneous coronary
thrombosis.2,18 A substantial number of
patients have an incomplete response
to intravenous immunoglobulin and
require additional treatment. Unresponsive patients are at high risk of coronary
abnormalities and adverse events resulting from multiple therapies.23 In 13%
to 30% of KD patients, fever persists or
recurs. Fever may recur several days after
hospital discharge. Doctors must bear
the responsibility of warning parents to
return to the hospital if fever or other
signs of KD recur; inadequate discharge
instructions put patients at risk for developing coronary artery abnormalities.24
Untreated recurrences can lead to aneurism of the coronary arteries, myocarditis,25 toxic shock,26 and sudden death.27
Sudden death from MI can occur many
years later in individuals who developed
CAA and stenoses in childhood.28

Ongoing Surveillance
Developing and maintaining a KD-specific national registry or a KD surveillance
system may help reduce the nationwide
incidence of KD. National and state incidence is difficult to estimate, because
reporting of KD cases to the Centers for
Disease Control and Prevention remains
sporadic,9 and all tracking and reporting
is left to state agencies to enforce.29 As
with any large passive surveillance system, only a fraction of cases is reported.22
Researchers are forced to rely on hospital
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discharge data.15 The central public health
policy problems related to KD are the
need to educate clinicians, and the need
for a government policy ensuring the
timely acquisition of accurate data for all
suspected KD cases for purposes of early
diagnosis, patient tracking, and determining the cause of the disease.10

Continuing Medical
Education
Although KD is now the leading cause
of acquired heart disease among children
in developed countries,30 its etiology remains unknown. To diagnose KD early
and accurately, clinicians must be educated
to recognize the signs and symptoms of
KD and make differential diagnoses. This
training should begin in medical schools
and continue through continuing medical
education courses. Pediatricians, emergency medicine physicians, and primary
care physicians must stay abreast of the
latest developments in pediatric medicine
and infectious diseases. Continuing medical education has become increasingly
important to the management of KD because of the serious and sometimes fatal
consequences of delayed treatment caused
by erroneous diagnoses. If professional associations and state licensure boards were
to require KD-specific education, perhaps
the national rate of misdiagnosis could be
significantly reduced.

Conclusion
Because KD is the leading cause of
acquired heart disease among children in
the US, and considering the sudden deaths
that result from coronary aneurysm and
thrombosis, effective management of KD
would substantially benefit public health.8
It is imperative to educate physicians
and other clinicians, including nurses, to
recognize the signs and symptoms of KD,
because delayed or erroneous diagnoses
delay treatment and sometimes lead to
death. This also hinders cost containment efforts at the national level. Active
surveillance could potentially yield longterm benefits for clinicians, patients, and
society as a whole by facilitating the
identification, prevention, and treatment
of KD. The financial costs and benefits of
accurate diagnosis and treatment may be
further quantifiable when more accurate
data are available. v
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The Principle of Life
Since all living things are warm, all dying things cold,
there must be a … seat and fountain,
a kind of home and hearth, where the cherisher of nature,
the original of the native fire, is stored and preserved;
from which heat and life are dispensed to all parts as from a fountain head;
from which sustenance may be derived; and upon which concoction and nutrition,
and all vegetative energy may depend. Now that the heart is this place,
that the heart is the principle of life … I trust no one will deny.
— On Circulation of the Blood, William Harvey, 1578 – 1657, English physician and first person to describe completely
and in detail the systemic circulation and properties of blood being pumped through the body by the heart
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